GLP-1s in the Real World: What Adherence, Diet Coaching, and Combo Therapy Actually Look Like

The newest real-world readout on oral semaglutide is, by the standards of this field, reassuring. A pooled analysis of seven PIONEER REAL studies across Canada, Denmark, Italy, the Netherlands, Sweden, Switzerland and the UK followed 1,615 adults with type 2 diabetes who started oral semaglutide in routine care. By the end of the 38-week observation window, 76% were still on treatment — a meaningful figure in a drug class where gastrointestinal side effects often push people off therapy. Average HbA1C fell by roughly one percentage point and body weight by about 5%. Patient-reported treatment satisfaction rose significantly over the same period.

None of those numbers are miraculous, and they are not meant to be. A one-point A1C drop and a 5% weight loss are the kind of outcomes that, sustained, move a person's ten-year cardiovascular risk in the right direction. What matters is that they held up across seven health systems with different prescribing cultures, different food environments and different patient mixes — the closest thing we have to evidence that the trial results translate to a Tuesday afternoon clinic.

For many women over 55, the more pressing clinical question is not GLP-1 versus nothing but GLP-1 alongside what is already in the medicine cabinet. SGLT2 inhibitors — empagliflozin, dapagliflozin and their siblings — have become foundational therapy for type 2 diabetes with cardiovascular or kidney risk, and they are often prescribed before a GLP-1 enters the picture. Whether the two classes still pull their weight together has been an open question.

A SMART-C collaborative meta-analysis of randomized trials, summarized in Annals of Internal Medicine, suggests they do. Across the pooled trials, the cardiovascular and kidney benefits of SGLT2 inhibitors appeared consistent regardless of whether participants were also taking a GLP-1 receptor agonist. In plain terms: adding a GLP-1 does not seem to erode the cardiorenal protection patients are getting from their SGLT2 inhibitor, and the two classes appear to act through complementary, not redundant, pathways.

That is a meta-analytic signal, not a license to self-stack medications. The trials were not designed primarily to test the combination, and the right sequence for any given patient still belongs to the clinician who knows her kidney function, her blood pressure and her history with each drug class. But for readers who have wondered whether starting a GLP-1 means quietly giving up on the protection their SGLT2 inhibitor was supposed to deliver, the current evidence does not support that worry.

The third piece of evidence is the one most often missing from the marketing. A qualitative study of registered dietitians working with patients on GLP-1 medications laid out, in their own words, what separates a smooth first six months from a discouraging one. Their composite picture: side effects are manageable but not self-managing; visual and metaphorical aids help patients understand what the drug is doing to appetite and digestion; structured lifestyle programs outperform vague counseling; and personalized diet plans — especially around protein adequacy, fiber, hydration and meal timing — are the scaffolding that keeps weight loss from becoming muscle loss.

The dietitians' observations are not a randomized trial, and the study does not quantify how much adherence improves with better coaching. What it documents is the practical anatomy of a protocol that works: proactive conversations about nausea and constipation before they happen, written plans rather than verbal advice, and ongoing follow-up rather than a single hand-off at the prescription. For women navigating menopausal shifts in appetite, sleep and body composition at the same time, that scaffolding is not optional. It is the intervention.

The reason these three pieces of evidence belong in the same article is that they answer the questions readers are actually asking, in roughly the order they tend to arise. Will it work for someone like me? Probably modestly, and probably enough to matter. Will it interfere with the cardiometabolic medications I am already on? Current evidence suggests no — at least not for SGLT2 inhibitors. And if I start, what will the first six months actually require of me? More structure than the prescription pad implies, and ideally a dietitian in the room.

None of this resolves the larger questions about long-term use, what happens when these drugs are stopped, or how the next generation of dual and triple agonists will reshape the landscape. Those answers are still being written. But the current evidence — moderate, real-world, and increasingly consistent — supports a measured optimism. The drugs work outside the trial. They appear to play well with the medicines they are most often combined with. And the people who coach patients through them know what helps. The remaining task, for any individual reader, is to bring those three findings into the room with the clinician who knows her best.